Order byBest matchMost fresh

Sarepta Will Resume Gene Therapy Shipments

Digest more
Sarepta shares rebound after shipments of gene therapy Elevidys resume in US
By Bhanvi Satija and Siddhi Mahatole (Reuters) -Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for its muscular gene therapy soothes immediate concerns about liquidity and the therapy's withdrawal from the market.

Continue reading

Sarepta will resume gene therapy shipments after FDA review of recent patient death
Sarepta's FDA woes raise questions for future of gene therapy treatments
Sarepta Shares Rise After Company Says It Will Resume Elevidys Shipments
Shares of Sarepta surged Tuesday, a day after the FDA said the company could lift a voluntary pause on shipments of its Elevidys drug, which had been linked to three patient deaths this year.

Continue reading

FDA allows Sarepta to resume some Elevidys shipments
Sarepta Therapeutics to Lift Pause on Shipments of Duchenne Treatment Elevidys
FDA recommends lifting voluntary hold on Elevidys in ambulatory patients
The agency stated that it will continue to work with the sponsor on non-ambulatory patients, who are still subject to a voluntary hold following two deaths.

Continue reading

Parents call on FDA for path forward after Duchenne's gene therapy pause | Morning in America
STAT · 23h
FDA permits use of Sarepta Therapeutics’ Duchenne therapy in younger patients after short-lived halt
FDA Lifts Safety Hold On Sarepta's Muscular Dystrophy Gene Therapy—Wall Street Cheers
Sarepta stock sees upgrades and price hikes as analysts reassess Elevidys prospects following a favorable FDA development.
Sarepta fails to win EU backing for muscle disorder gene therapy
Sarepta Therapeutics failed to win the European drug regulator's backing for its muscle disorder gene therapy on Friday, as the company faces intense regulatory scrutiny after two recent patient deaths tied to the treatment.
Sarepta: SRPT Stock To $40?
This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially double from current levels to around $40
Two boys died after a gene therapy. This family won’t give up hope.
The Revell family hoped a gene therapy could buy time for their sons, who have a rare and fatal disease. After two patients died, the drug’s manufacturer halted dosing under pressure from the FDA.
Feedback